ERBB2 and breast carcinoma: Since lysosome uptake of trastuzumab degrades HER2 receptors, resulting in cell death, the authors hypothesized that trastuzumab-AuNP-111In might be toxic to breast cancer cells in two ways, by reducing HER2 and by causing DNA damage in breast cancer cells, owing to Auger electron emission.